Idelalisib + Rituximab

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Lymphocytic Leukaemia

Conditions

Chronic Lymphocytic Leukaemia

Trial Timeline

Sep 12, 2018 → Mar 26, 2019

NCT ID

NCT03582098

About Idelalisib + Rituximab

Idelalisib + Rituximab is a pre-clinical stage product being developed by Gilead Sciences for Chronic Lymphocytic Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03582098. Target conditions include Chronic Lymphocytic Leukaemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02136511	Pre-clinical	Completed	—	—	Chronic Lymphocytic Leukemia (CLL)
NCT03582098	Pre-clinical	Completed	Sep 12, 2018	Mar 26, 2019	Chronic Lymphocytic Leukaemia
NCT02258529	Phase 2	Terminated	Sep 14, 2015	May 3, 2016	Follicular Lymphoma
NCT02044822	Phase 2	Terminated	Aug 6, 2014	May 17, 2016	B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
NCT01203930	Phase 2	Terminated	Oct 1, 2010	Jun 1, 2016	Chronic Lymphocytic Leukemia (CLL)

Competing Products

20 competing products in Chronic Lymphocytic Leukaemia

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved